Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 48 | 2023 | 1591 | 4.750 |
Why?
|
Hepacivirus | 46 | 2023 | 1379 | 4.170 |
Why?
|
Hepatitis B | 10 | 2024 | 695 | 1.690 |
Why?
|
Hepatitis C, Chronic | 19 | 2023 | 1031 | 1.660 |
Why?
|
Antiviral Agents | 33 | 2024 | 2987 | 1.570 |
Why?
|
CD8-Positive T-Lymphocytes | 24 | 2022 | 4477 | 1.030 |
Why?
|
Substance Abuse, Intravenous | 10 | 2023 | 525 | 0.950 |
Why?
|
Hepatitis B, Chronic | 6 | 2024 | 393 | 0.900 |
Why?
|
Interleukins | 3 | 2017 | 791 | 0.840 |
Why?
|
HIV Infections | 23 | 2024 | 16718 | 0.760 |
Why?
|
Protease Inhibitors | 4 | 2015 | 791 | 0.720 |
Why?
|
Drug Users | 3 | 2023 | 134 | 0.710 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 252 | 0.680 |
Why?
|
Ribavirin | 8 | 2021 | 395 | 0.640 |
Why?
|
Hepatitis B virus | 8 | 2024 | 513 | 0.620 |
Why?
|
Interferons | 8 | 2020 | 706 | 0.610 |
Why?
|
Hepatitis, Viral, Human | 1 | 2017 | 138 | 0.580 |
Why?
|
Drug Resistance, Viral | 4 | 2010 | 820 | 0.580 |
Why?
|
RNA, Viral | 12 | 2013 | 2902 | 0.580 |
Why?
|
Specialization | 1 | 2020 | 777 | 0.520 |
Why?
|
HLA-B Antigens | 3 | 2011 | 353 | 0.510 |
Why?
|
Prisoners | 4 | 2013 | 297 | 0.490 |
Why?
|
Major Histocompatibility Complex | 1 | 2017 | 936 | 0.490 |
Why?
|
Needle Sharing | 1 | 2013 | 24 | 0.480 |
Why?
|
Communicable Disease Control | 2 | 2020 | 857 | 0.470 |
Why?
|
Interferon-alpha | 5 | 2019 | 895 | 0.460 |
Why?
|
Epitopes, T-Lymphocyte | 16 | 2013 | 880 | 0.450 |
Why?
|
Viral Nonstructural Proteins | 7 | 2013 | 241 | 0.430 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2022 | 4385 | 0.390 |
Why?
|
Oligopeptides | 3 | 2015 | 1178 | 0.380 |
Why?
|
Viremia | 6 | 2012 | 736 | 0.360 |
Why?
|
HIV-1 | 7 | 2013 | 6938 | 0.350 |
Why?
|
Mass Screening | 4 | 2021 | 5252 | 0.350 |
Why?
|
Viral Load | 8 | 2020 | 3300 | 0.310 |
Why?
|
HLA-B27 Antigen | 3 | 2013 | 76 | 0.310 |
Why?
|
Polyethylene Glycols | 3 | 2009 | 1181 | 0.300 |
Why?
|
Virus Replication | 6 | 2013 | 2534 | 0.290 |
Why?
|
Hepatitis C Antibodies | 5 | 2013 | 145 | 0.280 |
Why?
|
Immunologic Memory | 2 | 2021 | 1348 | 0.250 |
Why?
|
Humans | 97 | 2024 | 744220 | 0.240 |
Why?
|
Rheumatic Diseases | 2 | 2021 | 593 | 0.240 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7281 | 0.240 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 657 | 0.230 |
Why?
|
Physicians | 1 | 2020 | 4564 | 0.210 |
Why?
|
Antigens, Viral | 2 | 2021 | 1035 | 0.200 |
Why?
|
Epitopes | 3 | 2021 | 2571 | 0.190 |
Why?
|
Male | 49 | 2021 | 350027 | 0.190 |
Why?
|
Cohort Studies | 16 | 2022 | 40559 | 0.180 |
Why?
|
Genotype | 9 | 2017 | 12956 | 0.180 |
Why?
|
Immunodominant Epitopes | 3 | 2011 | 267 | 0.170 |
Why?
|
Liver Diseases | 3 | 2020 | 1254 | 0.170 |
Why?
|
Hepatitis D | 1 | 2019 | 18 | 0.170 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.170 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 418 | 0.170 |
Why?
|
Kidney Failure, Chronic | 2 | 2023 | 2538 | 0.170 |
Why?
|
Jaundice | 1 | 2019 | 89 | 0.170 |
Why?
|
Acute Disease | 9 | 2017 | 7148 | 0.160 |
Why?
|
Latent Tuberculosis | 1 | 2021 | 225 | 0.160 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.160 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2019 | 1366 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3132 | 0.160 |
Why?
|
Female | 43 | 2021 | 380197 | 0.160 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.160 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3239 | 0.160 |
Why?
|
Liver | 5 | 2020 | 7472 | 0.150 |
Why?
|
Adult | 31 | 2022 | 214035 | 0.150 |
Why?
|
Infectious Disease Medicine | 1 | 2017 | 46 | 0.150 |
Why?
|
Middle Aged | 34 | 2020 | 213367 | 0.140 |
Why?
|
Ritonavir | 3 | 2023 | 322 | 0.140 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4259 | 0.140 |
Why?
|
Immunity, Innate | 4 | 2020 | 2958 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17449 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2234 | 0.130 |
Why?
|
Receptors, Fc | 1 | 2019 | 541 | 0.130 |
Why?
|
Piperidines | 2 | 2021 | 1605 | 0.130 |
Why?
|
Cryoglobulinemia | 1 | 2015 | 87 | 0.130 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 70 | 0.130 |
Why?
|
HLA-A Antigens | 3 | 2010 | 231 | 0.130 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.120 |
Why?
|
North America | 1 | 2017 | 1250 | 0.120 |
Why?
|
Comorbidity | 5 | 2020 | 10387 | 0.120 |
Why?
|
DNA, Viral | 4 | 2024 | 2226 | 0.120 |
Why?
|
Interferon Type I | 1 | 2017 | 542 | 0.120 |
Why?
|
Professional Role | 1 | 2016 | 306 | 0.110 |
Why?
|
Disease Progression | 6 | 2020 | 13280 | 0.110 |
Why?
|
HIV | 2 | 2019 | 1604 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 133 | 0.110 |
Why?
|
Homosexuality, Male | 2 | 2012 | 1240 | 0.110 |
Why?
|
Antigen Presentation | 2 | 2010 | 1284 | 0.110 |
Why?
|
Genes, MHC Class I | 2 | 2010 | 258 | 0.110 |
Why?
|
Polysaccharides | 1 | 2019 | 1053 | 0.110 |
Why?
|
Phylogeny | 6 | 2009 | 2803 | 0.110 |
Why?
|
Vaccination | 2 | 2021 | 3278 | 0.100 |
Why?
|
Pyrimidines | 2 | 2021 | 2940 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 350 | 0.100 |
Why?
|
Seroepidemiologic Studies | 1 | 2013 | 402 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2214 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2011 | 2563 | 0.100 |
Why?
|
Suppression, Genetic | 1 | 2011 | 196 | 0.100 |
Why?
|
Proline | 3 | 2021 | 458 | 0.100 |
Why?
|
Young Adult | 11 | 2020 | 56436 | 0.100 |
Why?
|
Europe | 1 | 2017 | 3339 | 0.100 |
Why?
|
Antigens, Surface | 2 | 2022 | 1663 | 0.090 |
Why?
|
Prisons | 2 | 2010 | 161 | 0.090 |
Why?
|
2-Naphthylamine | 2 | 2021 | 23 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2015 | 851 | 0.090 |
Why?
|
HLA Antigens | 3 | 2011 | 1382 | 0.090 |
Why?
|
Syphilis | 1 | 2012 | 227 | 0.090 |
Why?
|
Placenta | 1 | 2019 | 1697 | 0.090 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 2133 | 0.090 |
Why?
|
Cause of Death | 1 | 2020 | 3584 | 0.090 |
Why?
|
Immunity, Active | 1 | 2009 | 60 | 0.090 |
Why?
|
Creatinine | 1 | 2015 | 1919 | 0.090 |
Why?
|
Psychoses, Substance-Induced | 1 | 2010 | 96 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.080 |
Why?
|
Macrocyclic Compounds | 3 | 2019 | 72 | 0.080 |
Why?
|
Uracil | 2 | 2021 | 165 | 0.080 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2009 | 102 | 0.080 |
Why?
|
Cyclopropanes | 2 | 2021 | 416 | 0.080 |
Why?
|
Remission, Spontaneous | 4 | 2013 | 380 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2012 | 676 | 0.080 |
Why?
|
Viral Proteins | 4 | 2010 | 1900 | 0.080 |
Why?
|
Lactams, Macrocyclic | 2 | 2021 | 320 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4252 | 0.080 |
Why?
|
Aged | 19 | 2020 | 163253 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1971 | 0.080 |
Why?
|
Tissue Donors | 1 | 2017 | 2242 | 0.080 |
Why?
|
Survival Analysis | 2 | 2013 | 10250 | 0.080 |
Why?
|
Immunoassay | 2 | 2012 | 752 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2170 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2019 | 4559 | 0.070 |
Why?
|
T-Lymphocytes | 4 | 2009 | 10182 | 0.070 |
Why?
|
Pilot Projects | 4 | 2015 | 8321 | 0.070 |
Why?
|
Mutation | 7 | 2011 | 29784 | 0.070 |
Why?
|
HLA-A3 Antigen | 1 | 2006 | 34 | 0.070 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 256 | 0.070 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 71 | 0.070 |
Why?
|
Lymphocyte Activation | 6 | 2019 | 5523 | 0.070 |
Why?
|
Cross Infection | 1 | 2015 | 1416 | 0.070 |
Why?
|
Epitope Mapping | 1 | 2007 | 311 | 0.070 |
Why?
|
Recombinant Proteins | 4 | 2009 | 6612 | 0.070 |
Why?
|
Tryptophan Synthase | 2 | 1995 | 9 | 0.070 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 25043 | 0.070 |
Why?
|
Meningitis, Bacterial | 1 | 2007 | 218 | 0.070 |
Why?
|
Liver Function Tests | 2 | 2020 | 528 | 0.070 |
Why?
|
HLA-B8 Antigen | 1 | 2004 | 19 | 0.060 |
Why?
|
Lectins, C-Type | 1 | 2008 | 588 | 0.060 |
Why?
|
United States | 6 | 2021 | 69867 | 0.060 |
Why?
|
Lymphocyte Count | 1 | 2006 | 793 | 0.060 |
Why?
|
Program Evaluation | 1 | 2013 | 2486 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1821 | 0.060 |
Why?
|
Psychiatry | 1 | 2016 | 1695 | 0.060 |
Why?
|
Treatment Outcome | 9 | 2017 | 63119 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2147 | 0.060 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2004 | 84 | 0.060 |
Why?
|
Alanine Transaminase | 2 | 2020 | 592 | 0.060 |
Why?
|
Hydroxylamines | 1 | 2023 | 40 | 0.060 |
Why?
|
Interferon-gamma | 3 | 2007 | 3203 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 547 | 0.060 |
Why?
|
Shame | 1 | 2023 | 78 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7723 | 0.060 |
Why?
|
Temporal Bone | 1 | 2007 | 661 | 0.060 |
Why?
|
Risk Factors | 6 | 2020 | 72280 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2024 | 305 | 0.050 |
Why?
|
Genome-Wide Association Study | 3 | 2017 | 12264 | 0.050 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 742 | 0.050 |
Why?
|
Logistic Models | 2 | 2015 | 13409 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9849 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2017 | 15525 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2007 | 1157 | 0.050 |
Why?
|
Canada | 2 | 2021 | 2065 | 0.050 |
Why?
|
Immunity, Cellular | 2 | 2007 | 1607 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 2 | 2007 | 2559 | 0.050 |
Why?
|
Lung | 1 | 2020 | 9852 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2013 | 2118 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3558 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 2 | 2014 | 82 | 0.050 |
Why?
|
Antigens, CD | 2 | 2013 | 4026 | 0.050 |
Why?
|
Cerebrospinal Fluid | 1 | 2004 | 534 | 0.050 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2009 | 1873 | 0.050 |
Why?
|
High Mobility Group Proteins | 1 | 2021 | 187 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 6485 | 0.050 |
Why?
|
Sulfonamides | 2 | 2021 | 1940 | 0.050 |
Why?
|
Recurrence | 2 | 2016 | 8343 | 0.050 |
Why?
|
Massachusetts | 3 | 2020 | 8663 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
Surface-Active Agents | 1 | 2020 | 159 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2005 | 986 | 0.040 |
Why?
|
Phenotype | 4 | 2021 | 16365 | 0.040 |
Why?
|
Liver Cirrhosis | 2 | 2024 | 1864 | 0.040 |
Why?
|
Risk Assessment | 4 | 2022 | 23337 | 0.040 |
Why?
|
Valine | 1 | 2021 | 413 | 0.040 |
Why?
|
Belgium | 1 | 2019 | 103 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39045 | 0.040 |
Why?
|
Glycerophosphates | 2 | 1995 | 48 | 0.040 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2020 | 311 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2004 | 1043 | 0.040 |
Why?
|
Cytokines | 2 | 2022 | 7326 | 0.040 |
Why?
|
Cell Degranulation | 1 | 2019 | 287 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 405 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6172 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2019 | 175 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2010 | 2400 | 0.040 |
Why?
|
Carbamates | 2 | 2010 | 196 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1420 | 0.040 |
Why?
|
Amino Acid Sequence | 5 | 2009 | 13817 | 0.040 |
Why?
|
Anti-Retroviral Agents | 1 | 2007 | 1715 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 627 | 0.040 |
Why?
|
Mucins | 1 | 2020 | 564 | 0.040 |
Why?
|
Peptides | 2 | 2007 | 4407 | 0.040 |
Why?
|
Immunomodulation | 1 | 2021 | 541 | 0.040 |
Why?
|
Autopsy | 1 | 2020 | 1021 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2010 | 5021 | 0.040 |
Why?
|
In Situ Hybridization | 1 | 2020 | 1950 | 0.040 |
Why?
|
Mental Disorders | 1 | 2016 | 6601 | 0.040 |
Why?
|
Salmonella typhimurium | 2 | 1995 | 351 | 0.040 |
Why?
|
Brazil | 2 | 2011 | 1270 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1126 | 0.030 |
Why?
|
Health Personnel | 1 | 2009 | 3216 | 0.030 |
Why?
|
Pandemics | 3 | 2020 | 8387 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2019 | 582 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 29050 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 895 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2020 | 77426 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57768 | 0.030 |
Why?
|
Protein Conformation | 2 | 2010 | 4012 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2017 | 336 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2014 | 27 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2619 | 0.030 |
Why?
|
Immunity | 1 | 2020 | 1012 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 91 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2012 | 1475 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 969 | 0.030 |
Why?
|
Quinolines | 2 | 2010 | 730 | 0.030 |
Why?
|
Perforin | 1 | 2014 | 168 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 4256 | 0.030 |
Why?
|
Genome, Viral | 2 | 2007 | 667 | 0.030 |
Why?
|
Evolution, Molecular | 3 | 2007 | 1939 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9960 | 0.030 |
Why?
|
Amino Acids | 2 | 2010 | 1734 | 0.030 |
Why?
|
Amino Acid Substitution | 2 | 2010 | 1792 | 0.030 |
Why?
|
Molecular Sequence Data | 4 | 2007 | 18116 | 0.030 |
Why?
|
Tryptophan | 1 | 1994 | 479 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2017 | 713 | 0.030 |
Why?
|
Time Factors | 2 | 2017 | 40063 | 0.030 |
Why?
|
Biopsy | 1 | 2004 | 6757 | 0.030 |
Why?
|
Thiazoles | 2 | 2010 | 1484 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4929 | 0.030 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
Adolescent | 4 | 2019 | 85759 | 0.020 |
Why?
|
Prevalence | 1 | 2007 | 15226 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2715 | 0.020 |
Why?
|
Point Mutation | 1 | 1995 | 1624 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5396 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 623 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2010 | 126 | 0.020 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2009 | 52 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 52 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 347 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15161 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1880 | 0.020 |
Why?
|
Chromatin | 1 | 2021 | 2934 | 0.020 |
Why?
|
Needlestick Injuries | 1 | 2009 | 67 | 0.020 |
Why?
|
Australia | 1 | 2012 | 1169 | 0.020 |
Why?
|
Phenylthiourea | 1 | 2008 | 11 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1504 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12961 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3871 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1781 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1708 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2021 | 11478 | 0.020 |
Why?
|
Animals | 3 | 2009 | 168788 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3690 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2017 | 1582 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15538 | 0.020 |
Why?
|
Earache | 1 | 2007 | 15 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2017 | 1702 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3646 | 0.020 |
Why?
|
Netherlands | 1 | 2012 | 2170 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10949 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9311 | 0.020 |
Why?
|
Pneumocephalus | 1 | 2007 | 46 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6938 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1423 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3680 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6308 | 0.020 |
Why?
|
Incidence | 3 | 2012 | 20945 | 0.020 |
Why?
|
Genetic Variation | 2 | 2017 | 6546 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11368 | 0.020 |
Why?
|
Serotyping | 1 | 2007 | 338 | 0.020 |
Why?
|
Binding Sites | 2 | 2011 | 6116 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2007 | 377 | 0.020 |
Why?
|
Heart | 1 | 2020 | 4465 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12035 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2006 | 110 | 0.020 |
Why?
|
Speech Disorders | 1 | 2007 | 189 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 153 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2015 | 1772 | 0.020 |
Why?
|
5' Untranslated Regions | 1 | 2007 | 249 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5657 | 0.020 |
Why?
|
Ultrasonography | 1 | 2019 | 5982 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2007 | 1086 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3588 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12781 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 644 | 0.020 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2005 | 87 | 0.020 |
Why?
|
Unconsciousness | 1 | 2007 | 263 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3256 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3611 | 0.020 |
Why?
|
Chronic Disease | 3 | 2005 | 9147 | 0.020 |
Why?
|
Life Expectancy | 1 | 2012 | 1184 | 0.020 |
Why?
|
Intracranial Hypertension | 1 | 2007 | 186 | 0.020 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2007 | 323 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2012 | 1904 | 0.020 |
Why?
|
Models, Molecular | 2 | 2010 | 5458 | 0.020 |
Why?
|
Prospective Studies | 3 | 2016 | 53280 | 0.020 |
Why?
|
Cross Reactions | 1 | 2006 | 841 | 0.020 |
Why?
|
Haplotypes | 1 | 2010 | 2781 | 0.010 |
Why?
|
Cell Proliferation | 2 | 2012 | 10480 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12244 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 645 | 0.010 |
Why?
|
Risk-Taking | 1 | 2009 | 986 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2008 | 732 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2004 | 337 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5974 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2007 | 2256 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1849 | 0.010 |
Why?
|
Hepatitis C Antigens | 1 | 2002 | 34 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2007 | 2839 | 0.010 |
Why?
|
HIV Seropositivity | 1 | 2008 | 971 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 1978 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2002 | 213 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7908 | 0.010 |
Why?
|
Serine | 2 | 1995 | 828 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9438 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10634 | 0.010 |
Why?
|
Brain | 1 | 2007 | 26413 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2007 | 1836 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4567 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2007 | 15070 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2916 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5138 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2009 | 1796 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 25618 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3209 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12207 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29142 | 0.010 |
Why?
|
Kinetics | 2 | 1995 | 6474 | 0.010 |
Why?
|
Indoles | 2 | 1995 | 1838 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2013 | 7879 | 0.010 |
Why?
|
Radioisotope Dilution Technique | 1 | 1995 | 70 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14726 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4217 | 0.010 |
Why?
|
Genetic Testing | 1 | 2008 | 3443 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 4803 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21752 | 0.010 |
Why?
|
Base Sequence | 1 | 2007 | 12801 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15999 | 0.010 |
Why?
|
Mathematics | 1 | 1995 | 728 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1995 | 592 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7179 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2016 | 15294 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1995 | 1456 | 0.010 |
Why?
|
Catalysis | 1 | 1994 | 761 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1995 | 1724 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1995 | 3133 | 0.010 |
Why?
|
Crystallography, X-Ray | 1 | 1994 | 2012 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2002 | 5096 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 19227 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20123 | 0.000 |
Why?
|
Models, Theoretical | 1 | 1995 | 3591 | 0.000 |
Why?
|